Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera
A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-1...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/2/335 |
| _version_ | 1797476010575265792 |
|---|---|
| author | Wenhao Zhou Ping He Junhua Li Huan Liu Mengjuan Shi Junping Yu Hongping Wei |
| author_facet | Wenhao Zhou Ping He Junhua Li Huan Liu Mengjuan Shi Junping Yu Hongping Wei |
| author_sort | Wenhao Zhou |
| collection | DOAJ |
| description | A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-19. Here through ELISA assays using the recombinant RBD proteins with sequences the same to that of SARS-CoV-2 WIV04 (lineage B.1), the Delta variant and the Omicron variant as the coating antigens, the binding capabilities between the RBDs and the antibodies in COVID-19 convalescent sera and vaccine sera after two doses of the inactivated vaccine produced by Sinopharm WIBP are compared with each other. The results showed that the Omicron variant may evade antibodies induced by the ancestral strain and by the inactivated vaccine, with significant reduction in the binding capability of its RBD much greater than that of the Delta variant. |
| first_indexed | 2024-03-09T20:51:49Z |
| format | Article |
| id | doaj.art-af34cb5eba5643e294af79c4c5976a75 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T20:51:49Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-af34cb5eba5643e294af79c4c5976a752023-11-23T22:31:14ZengMDPI AGViruses1999-49152022-02-0114233510.3390/v14020335Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine SeraWenhao Zhou0Ping He1Junhua Li2Huan Liu3Mengjuan Shi4Junping Yu5Hongping Wei6CAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, ChinaA new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-19. Here through ELISA assays using the recombinant RBD proteins with sequences the same to that of SARS-CoV-2 WIV04 (lineage B.1), the Delta variant and the Omicron variant as the coating antigens, the binding capabilities between the RBDs and the antibodies in COVID-19 convalescent sera and vaccine sera after two doses of the inactivated vaccine produced by Sinopharm WIBP are compared with each other. The results showed that the Omicron variant may evade antibodies induced by the ancestral strain and by the inactivated vaccine, with significant reduction in the binding capability of its RBD much greater than that of the Delta variant.https://www.mdpi.com/1999-4915/14/2/335SARS-CoV-2Omicronvariants of concernantibodyreceptor-binding domaininactivated vaccine |
| spellingShingle | Wenhao Zhou Ping He Junhua Li Huan Liu Mengjuan Shi Junping Yu Hongping Wei Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera Viruses SARS-CoV-2 Omicron variants of concern antibody receptor-binding domain inactivated vaccine |
| title | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
| title_full | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
| title_fullStr | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
| title_full_unstemmed | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
| title_short | Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera |
| title_sort | steep decline in binding capability of sars cov 2 omicron variant b 1 1 529 rbd to the antibodies in early covid 19 convalescent sera and inactivated vaccine sera |
| topic | SARS-CoV-2 Omicron variants of concern antibody receptor-binding domain inactivated vaccine |
| url | https://www.mdpi.com/1999-4915/14/2/335 |
| work_keys_str_mv | AT wenhaozhou steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT pinghe steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT junhuali steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT huanliu steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT mengjuanshi steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT junpingyu steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera AT hongpingwei steepdeclineinbindingcapabilityofsarscov2omicronvariantb11529rbdtotheantibodiesinearlycovid19convalescentseraandinactivatedvaccinesera |